MCID: PRP036
MIFTS: 56

Peripheral T-Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Peripheral T-Cell Lymphoma

MalaCards integrated aliases for Peripheral T-Cell Lymphoma:

Name: Peripheral T-Cell Lymphoma 38 12 76 53 15 73
Peripheral T Cell Lymphoma 37
Lymphoma T-Cell Peripheral 55

Classifications:



External Ids:

Disease Ontology 12 DOID:0050749
KEGG 37 H01892
ICD10 33 C84.4
UMLS 73 C0079774

Summaries for Peripheral T-Cell Lymphoma

Disease Ontology : 12 A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus.

MalaCards based summary : Peripheral T-Cell Lymphoma, also known as peripheral t cell lymphoma, is related to angioimmunoblastic t-cell lymphoma and anaplastic large cell lymphoma, and has symptoms including pruritus An important gene associated with Peripheral T-Cell Lymphoma is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Beleodaq and Folotyn have been mentioned in the context of this disorder. Affiliated tissues include t cells, thymus and b cells, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 76 Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the... more...

Related Diseases for Peripheral T-Cell Lymphoma

Diseases related to Peripheral T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 angioimmunoblastic t-cell lymphoma 32.3 BCL6 CXCL13 ITK MME
2 anaplastic large cell lymphoma 31.3 ALK GZMB TNFRSF8
3 lymphoma 31.3 ALK BCL6 TCL1A TNFRSF8
4 adult t-cell leukemia 31.1 IL2 TNFRSF8 TP53
5 alk-negative anaplastic large cell lymphoma 31.0 ALK CCR4 CXCR3
6 lethal midline granuloma 30.9 NCAM1 TIA1
7 lymphomatoid papulosis 30.8 ALK GZMB TIA1
8 panniculitis 30.7 GZMB NCAM1 TIA1
9 cutaneous t cell lymphoma 30.5 CCR4 GZMB IL2 TIA1 TNFRSF8
10 subcutaneous panniculitis-like t-cell lymphoma 30.5 GZMB NCAM1 TIA1
11 lymphoma, hodgkin, classic 30.4 ALK BCL6 GZMB IL2 TIA1
12 t-cell large granular lymphocyte leukemia 30.4 GZMB IL2 NCAM1
13 composite lymphoma 30.3 BCL6 CD5 GZMB TIA1
14 cll/sll 30.3 CD5 MME TP53
15 follicular lymphoma 30.0 BCL6 MME MS4A1
16 marginal zone b-cell lymphoma 30.0 BCL6 CD5 MME
17 lymphoblastic lymphoma 29.9 BCL6 CD5 MME
18 mycosis fungoides 29.9 CCR4 CXCR3 GZMB IL2 TIA1 TNFRSF8
19 diffuse large b-cell lymphoma 29.6 ALK BCL6 CD5 MME TNFRSF8 TP53
20 hemophagocytic lymphohistiocytosis 29.4 CD5 GZMB IL2RB ITK
21 t-cell leukemia 29.3 CCR4 IL2 IL2RB TCL1A TNFRSF8
22 mantle cell lymphoma 29.1 BCL6 CD5 MME SYK TP53
23 lymphoma, mucosa-associated lymphoid type 28.9 BCL6 CD5 CXCL13 CXCR3 MME
24 b-cell lymphomas 27.8 BCL6 CD5 MME MS4A1 SYK TCL1A
25 leukemia, chronic lymphocytic 27.3 BCL6 CD5 CXCR3 IL2 MS4A1 SYK
26 primary cutaneous peripheral t-cell lymphoma not otherwise specified 12.6
27 enteropathy-associated t-cell lymphoma 11.6
28 lichen sclerosus et atrophicus 10.9 GZMB TIA1
29 lymphomatoid granulomatosis 10.9 GZMB TIA1
30 parameningeal embryonal rhabdomyosarcoma 10.9 ALK TP53
31 viral esophagitis 10.9 GZMB TIA1
32 primary cutaneous anaplastic large cell lymphoma 10.8 ALK GZMB TIA1
33 lymphocytic gastritis 10.7 GZMB TIA1
34 fixed drug eruption 10.7 CCR4 IL2
35 pityriasis lichenoides 10.7 MS4A1 TNFRSF8
36 erythema multiforme 10.7 CXCR3 GZMB IL2
37 gallbladder lymphoma 10.7 BCL6 MME
38 heart lymphoma 10.6 BCL6 MME
39 sezary's disease 10.6 CCR4 IL2 TNFRSF8
40 orbit lymphoma 10.6 GZMB NCAM1 TIA1
41 marek disease 10.6 TNFRSF8 TP53
42 lung papillary adenocarcinoma 10.6 ALK TP53
43 lung combined type small cell carcinoma 10.5 MME NCAM1
44 lichen planus 10.5 CXCR3 GZMB TP53
45 t-cell/histiocyte rich large b cell lymphoma 10.5 BCL6 MME TNFRSF8
46 extrahepatic bile duct adenocarcinoma 10.5 MME NCAM1
47 tracheal lymphoma 10.5 CD5 MME
48 hodgkin's lymphoma, lymphocytic depletion 10.5 ALK TNFRSF8
49 cell type cancer 10.4 ALK IL2 TP53
50 central nervous system lymphoma 10.4 BCL6 IL2 TP53

Graphical network of the top 20 diseases related to Peripheral T-Cell Lymphoma:



Diseases related to Peripheral T-Cell Lymphoma

Symptoms & Phenotypes for Peripheral T-Cell Lymphoma

UMLS symptoms related to Peripheral T-Cell Lymphoma:


pruritus

GenomeRNAi Phenotypes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 BCL6 CD5 ETV6 ITK NCAM1 NME1

MGI Mouse Phenotypes related to Peripheral T-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 SYK TIA1 TNFRSF8 TP53 BCL6 CCR4
2 immune system MP:0005387 10.13 BCL6 CCR4 CD5 CXCL13 CXCR3 ETV6
3 endocrine/exocrine gland MP:0005379 10.07 ALK BCL6 ETV6 IL2 IL2RB ITK
4 liver/biliary system MP:0005370 9.7 BCL6 IL2 IL2RB MME NME1 SYK
5 neoplasm MP:0002006 9.43 IL2 NME1 TP53 ALK CXCR3 ETV6
6 respiratory system MP:0005388 9.17 ALK BCL6 CCR4 CXCR3 IL2 SYK

Drugs & Therapeutics for Peripheral T-Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
2
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
3
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009

Drugs for Peripheral T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 228)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
4
Epirubicin Approved Phase 4,Phase 1,Phase 2,Not Applicable 56420-45-2 41867
5
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
6
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-24-8 5755
13
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
14
Mechlorethamine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 51-75-2 4033
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
17
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
18
Pirarubicin Investigational Phase 4 72496-41-4
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
20 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 BB 1101 Phase 4,Phase 2,Phase 1,Early Phase 1
29 Dexamethasone acetate Phase 4,Phase 2,Phase 1,Early Phase 1 1177-87-3
30 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1 0
37 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
39 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 1,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Methylprednisolone acetate Phase 4,Phase 1,Phase 2,Not Applicable
45 Methylprednisolone Hemisuccinate Phase 4,Phase 1,Phase 2,Not Applicable
46 Prednisolone acetate Phase 4,Phase 1,Phase 2,Not Applicable
47 Prednisolone hemisuccinate Phase 4,Phase 1,Phase 2,Not Applicable
48 Prednisolone phosphate Phase 4,Phase 1,Phase 2,Not Applicable
49 Antiemetics Phase 4,Phase 2,Phase 1,Early Phase 1
50 Autonomic Agents Phase 4,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 239)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
3 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
4 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4 Pralatrexate
5 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
6 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
7 Alemtuzumab and CHOP in T-cell Lymphoma Unknown status NCT00646854 Phase 3 CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
8 Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma Completed NCT00970385 Phase 3 CHOP21;VIP/ABVD
9 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Completed NCT01482962 Phase 3 Alisertib;Pralatrexate;Gemcitabine;Romidepsin
10 Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Active, not recruiting NCT01796002 Phase 3 Romidepsin + CHOP;CHOP
11 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL Active, not recruiting NCT03349333 Phase 3 pralatrexate
12 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
13 Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Not yet recruiting NCT03553537 Phase 3 Decitabine;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
14 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Not yet recruiting NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
15 Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Not yet recruiting NCT03355768 Phase 3 Romidepsin;Pralatrexate
16 Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients Terminated NCT01420679 Phase 3 Pralatrexate Injection
17 A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma Withdrawn NCT01355783 Phase 3 E7777
18 Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study Unknown status NCT02520219 Phase 2 GDP
19 Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma Unknown status NCT00136565 Phase 2 Velcade + ACVBP regimen
20 Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma Unknown status NCT00974324 Phase 2 endostar and CHOP
21 Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) Unknown status NCT00632827 Phase 2 REGIMEN;REGIMEN B
22 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Unknown status NCT00211185 Phase 2 ONTAK (denileukin diftitox, DAB389 IL-2)
23 Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) Unknown status NCT00840385 Phase 2 FAD
24 GDP in Frontline Chemotherapy for Patients With PTCL-NOS Unknown status NCT02404571 Phase 2 GDP chemotherapy
25 A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. Unknown status NCT00299351 Phase 2 Depsipeptide
26 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
27 Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma Unknown status NCT01307592 Phase 2 gemcitabine hydrochloride;lenalidomide;oxaliplatin
28 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
29 Allo-hNHL (FluBuCy) Unknown status NCT00785330 Phase 2 standard GVHD prophylaxis;rituximab
30 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid
31 CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma Completed NCT01806337 Phase 2 Alemtuzumab
32 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT00865969 Phase 2 PXD101
33 Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma Completed NCT00888927 Phase 1, Phase 2
34 The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) Completed NCT00930605 Phase 2 CHOP regimen alternate with ESHAP regimen;Alemtuzumab
35 Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT00364923 Phase 2 Pralatrexate Injection
36 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Completed NCT00007345 Phase 2 Romidepsin
37 Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) Completed NCT01611142 Phase 2
38 Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT02013362 Phase 1, Phase 2 Pralatrexate injection
39 A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas Completed NCT01280526 Phase 1, Phase 2 Romidepsin and CHOP;Romidepsin and CHOP;Romidepsin and CHOP;Romidepsin and CHOP
40 Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas Completed NCT00453427 Phase 1, Phase 2 Alemtuzumab (Campath-1H)
41 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
42 A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma Completed NCT00337987 Phase 2 Ontak;CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
43 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
44 A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT Completed NCT00791947 Phase 2 CHOEP + G-CSF followed by BEAM
45 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas Completed NCT02158975 Phase 2 MLN9708
46 Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma Completed NCT01679860 Phase 2 Clin B (CHOP- CAMPATH) Chemo-immunotherapy
47 Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients Completed NCT01776411 Phase 1, Phase 2 forodesine hydrochloride
48 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma Completed NCT00290433 Phase 2 Cyclophosphamide;Mesna;Vincristine;Methotrexate;Ara-C;Dexamethasone;G-CSF;Doxil
49 Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms Completed NCT00217425 Phase 2 cyclophosphamide;doxorubicin;prednisone;vincristine
50 Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas Completed NCT00374699 Phase 1, Phase 2 Velcade

Search NIH Clinical Center for Peripheral T-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral T-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Peripheral T-Cell Lymphoma

Anatomical Context for Peripheral T-Cell Lymphoma

MalaCards organs/tissues related to Peripheral T-Cell Lymphoma:

41
T Cells, Thymus, B Cells, Bone, Nk Cells, Bone Marrow, Liver

Publications for Peripheral T-Cell Lymphoma

Articles related to Peripheral T-Cell Lymphoma:

(show top 50) (show all 761)
# Title Authors Year
1
Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. ( 29674443 )
2018
2
Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) presenting as an endobronchial lesion: Case report and literature review. ( 29719812 )
2018
3
Clinicopathological analysis of immunohistochemical expression of retinoic acid-related orphan receptor-I^t in peripheral T-cell lymphoma, not otherwise specified. ( 29775622 )
2018
4
Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases. ( 29682368 )
2018
5
An autopsy case of peripheral T cell lymphoma occurring in a postpartum woman: a unique case suggesting changes in the immunocharacteristics of lymphoma cells before and after delivery. ( 29788970 )
2018
6
Dual-Positive CD4/CD8 Primary Cutaneous Peripheral T-Cell Lymphoma Previously Classified as Mycosis Fungoides a Tumor D'EmblAce. ( 29794483 )
2018
7
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
8
Central Nervous System Involvement in Peripheral T Cell Lymphoma. ( 29374824 )
2018
9
Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. ( 29974231 )
2018
10
Pathogenesis of Peripheral T Cell Lymphoma. ( 29414251 )
2018
11
STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma. ( 29682185 )
2018
12
Peripheral T-cell lymphoma: novel backbone. ( 29371206 )
2018
13
Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP. ( 29703333 )
2018
14
Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy. ( 29681823 )
2018
15
Frequency, distribution, and immunomorphologic characteristics of peripheral T-cell lymphoma, not otherwise specified in a tertiary care center in Southern India. ( 29676358 )
2018
16
Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy. ( 29269644 )
2018
17
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. ( 29703335 )
2018
18
Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review. ( 29951889 )
2018
19
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL). ( 29397528 )
2018
20
Decision analysis of up-front autologous hematopoietic stem cell transplantation in patients with peripheral T-cell lymphoma. ( 29795423 )
2018
21
A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. ( 29622656 )
2018
22
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. ( 29672827 )
2018
23
Pseudomonas oryzihabitans bacteremia in a child with peripheral T-cell lymphoma after allogeneic bone marrow transplantation. ( 29878628 )
2018
24
Epstein-Barr virus positive peripheral T cell lymphoma with novel variants in STAT5B of a pediatric patient: a case report. ( 29615001 )
2018
25
Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. ( 29719411 )
2018
26
Peripheral T-cell lymphoma mimicking classic Hodgkin's lymphoma in a patient presenting with fevers of unknown origin. ( 29420242 )
2018
27
Angioimmunoblastic T-cell lymphoma: a rare subtype of peripheral T-cell lymphoma. ( 29636953 )
2018
28
Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. ( 29662631 )
2018
29
Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. ( 29305415 )
2018
30
Expansion of NKG2C-expressing Natural Killer Cells after Umbilical Cord Blood Transplantation in a Patient with Peripheral T-Cell Lymphoma with Cytotoxic Molecules. ( 29269653 )
2017
31
Peripheral T-Cell Lymphoma of the Submandibular Salivary Gland as an Unusual Manifestation of Richter's Syndrome: A Case Report and Literature Review. ( 29410924 )
2017
32
Mutual regulation between BCL6 and a specific set of miRNAs controls TFH phenotype in peripheral T-cell lymphoma. ( 28699695 )
2017
33
Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers. ( 29253087 )
2017
34
Rapid Evolving Unilateral Indurated Oozing Facial Plaques in a Patient with Head-and-Neck Cancer: Peripheral T-Cell Lymphoma Not Otherwise Specified (NOS). ( 28785337 )
2017
35
Peripheral T-cell lymphoma cell line T8ML-1 highlights conspicuous targeting of PVRL2 by t(14;19)(q11.2;q13.3). ( 28659334 )
2017
36
Peripheral T-Cell Lymphoma in Mediastinum Lymph Nodes and Lung Associated to Histoplasmosis in a Patient with Chronic Lymphoid Leukemia/Small Lymphocytic Lymphoma. ( 28698787 )
2017
37
Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers. ( 29242582 )
2017
38
Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma. ( 28053548 )
2017
39
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. ( 28771889 )
2017
40
The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. ( 28597542 )
2017
41
Peripheral T-cell lymphoma, not otherwise specified. ( 29302559 )
2017
42
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. ( 28129454 )
2017
43
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. ( 28103725 )
2017
44
Mediastinal peripheral T-cell lymphoma diagnosed by repeated biopsies after an initial diagnosis of fibrosing mediastinitis. ( 28932400 )
2017
45
Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis. ( 28883272 )
2017
46
Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. ( 28664499 )
2017
47
Case of peripheral T-cell lymphoma, not otherwise specified, presenting dyshidrosis-like eruptions as the first clinical manifestation. ( 28868736 )
2017
48
Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. ( 27885817 )
2017
49
Primary hepatic peripheral T-cell lymphoma mimicking hepatocellular carcinoma: a case report. ( 28835888 )
2017
50
Treatment of Peripheral T-Cell Lymphoma in Community Settings. ( 28622960 )
2017

Variations for Peripheral T-Cell Lymphoma

Copy number variations for Peripheral T-Cell Lymphoma from CNVD:

7 (show all 12)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 88960 14 9867021 9882729 Gain BCL11B Peripheral t-cell lymphoma
2 88988 14 9896938 9916093 Gain CCNK Peripheral t-cell lymphoma
3 88989 14 9896938 9916093 Gain SETD3 Peripheral t-cell lymphoma
4 217122 7 1 59900000 Gain Peripheral t-cell lymphoma
5 226600 7 59900000 159138663 Gain Peripheral t-cell lymphoma
6 250160 9 2032100 2047878 Loss MLLT3 Peripheral t-cell lymphoma
7 250409 9 2120977 2133626 Loss IFNA17 Peripheral t-cell lymphoma
8 250410 9 2120977 2133626 Loss IFNA5 Peripheral t-cell lymphoma
9 250411 9 2120977 2133626 Loss KLHL9 Peripheral t-cell lymphoma
10 250672 9 2189825 2200141 Loss CDKN2A Peripheral t-cell lymphoma
11 250673 9 2189825 2200141 Loss CDKN2B Peripheral t-cell lymphoma
12 250674 9 2189825 2200141 Loss MTAP Peripheral t-cell lymphoma

Expression for Peripheral T-Cell Lymphoma

Search GEO for disease gene expression data for Peripheral T-Cell Lymphoma.

Pathways for Peripheral T-Cell Lymphoma

GO Terms for Peripheral T-Cell Lymphoma

Cellular components related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.56 ALK CCR4 CD5 CXCR3 IL2RB MME
2 external side of plasma membrane GO:0009897 9.1 CCR4 CD5 CXCR3 IL2RB MS4A1 NCAM1

Biological processes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.8 ALK BCL6 IL2 IL2RB TCL1A TP53
2 regulation of apoptotic process GO:0042981 9.77 ALK BCL6 NME1 TNFRSF8 TP53
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.71 CCR4 CXCL13 CXCR3 IL2
4 chemokine-mediated signaling pathway GO:0070098 9.65 CCR4 CXCL13 CXCR3
5 inflammatory response GO:0006954 9.63 BCL6 CCR4 CXCL13 CXCR3 SYK TNFRSF8
6 positive regulation of protein oligomerization GO:0032461 9.54 TCL1A TP53
7 replicative senescence GO:0090399 9.52 MME TP53
8 positive regulation of histone deacetylation GO:0031065 9.51 BCL6 TP53
9 positive regulation of regulatory T cell differentiation GO:0045591 9.49 BCL6 IL2
10 negative regulation of B cell apoptotic process GO:0002903 9.46 BCL6 IL2
11 germinal center formation GO:0002467 9.43 BCL6 CXCL13
12 leukocyte activation involved in immune response GO:0002366 9.26 IL2 SYK
13 interleukin-2-mediated signaling pathway GO:0038110 9.13 IL2 IL2RB SYK
14 regulation of cell proliferation GO:0042127 9.1 ALK BCL6 CXCL13 ITK SYK TNFRSF8

Molecular functions related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 ALK BCL6 CD5 ETV6 GZMB IL2

Sources for Peripheral T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....